Document is current
Any future updates will be listed below
-
Authors
Dammert, Marcel A.
Brägelmann, Johannes
Olsen, Rachelle R.
Böhm, Stefanie
Monhasery, Niloufar
Whitney, Christopher P.
Chalishazar, Milind D.
Tumbrink, Hannah L.
Guthrie, Matthew R.
Klein, Sebastian
Ireland, Abbie S.
Ryan, Jeremy http://orcid.org/0000-0002-3327-1283
Schmitt, Anna
Marx, Annika
Ozretić, Luka
Castiglione, Roberta
Lorenz, Carina
Jachimowicz, Ron D.
Wolf, Elmar http://orcid.org/0000-0002-5299-6335
Thomas, Roman K.
Poirier, John T. http://orcid.org/0000-0001-9795-5644
Büttner, Reinhard
Sen, Triparna
Byers, Lauren A.
Reinhardt, H. Christian
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Oliver, Trudy G. http://orcid.org/0000-0003-2082-2397
Sos, Martin L.
- License Information
-
More Information
Article History
Received: 30 November 2018
Accepted: 10 July 2019
First Online: 2 August 2019
Competing interests
: M.L.S. and R.K.T. are founders and shareholders of PearlRiver Bio. M.L.S. received a commercial research grant from Novartis. R.K.T. is a founder of NEO New Oncology GmbH, now part of Siemens Healthcare, and received consulting and lecture fees from Merck, Roche, Lilly, Boehringer Ingelheim, Astra-Zeneca, Daiichi-Sankyo, MSD, NEO New Oncology, Puma, and Clovis. H.C.R. received consulting and lecture fees from Abbvie, Astra-Zeneca, Vertex, and Merck and received research funding from Gilead Pharmaceuticals; R.B. is an employee of Targos Molecular Pathology. The other authors declare no competing interests.
